We’re excited to announce that the #COSIRAII clinical trial is expanding globally with new enrolling sites in the United Kingdom! COSIRA II is a multicenter, randomized, double-blinded, sham-controlled trial evaluating the #ShockwaveReducer for the treatment of patients with refractory angina. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in patients without documented obstructive coronary artery disease and abnormal coronary flow reserve (ANOCA). This clinical study represents the next wave of research and innovation for patients suffering from debilitating angina. To learn more about the COSIRA-II trial and the participating sites visit clinicaltrials.gov (clinicaltrials.gov/study/NCT…) ISI bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use.